Loading results
In the News
powered by Ovast-
FDA Panel Mixed On Pfizer's Rare Disease Drug - FierceBiotech
google.com 6 days, 17 hours agoUpdated News FDA panel mixed on Pfizer's rare disease drug FierceBiotech Pfizer's pioneering rare-disease drug tafamidis garnered mixed reviews from FDA advisers Thursday, casting further uncertainty over whether the agency will green-light the treatment for the US market. Both the agency's advisers and staff have harped on ... US panel split on Pfizer rare disease drug FDA Panel Sends Mixed Message on Pfizer Drug FDA Reviewer Recommends Against Approval Of Pfizer Drug -
-
Mixed Messages On Rare Disease Drug
abcnews.com 6 days, 2 hours agoAn FDA advisory panel said a study of Vyndaqel for familial amyloid polyneuropathy did not provide proof of its benefit, but that proof may not be necessary.
Photos
powered by
Loading photos for 'Nerve Disorders'
On Twitter
Loading tweets for 'Nerve Disorders'
Loading More Stories
